Landscape assessment of patient-reported outcome item coverage of tyrosine kinase inhibitor–associated adverse events
The EORTC and PRO-CTCAE covered more symptomatic adverse events than PROMIS. For the adverse events it covered, PROMIS had the most items assessing functional and social or emotional impact. Our assessment is a starting point for improving patient-reported outcome coverage of adverse events associated with new treatments such as tyrosine kinase inhibitors.
Authors
- Janet Freeman‐Daily (ORCID: https://orcid.org/0000-0003-3702-7912)
- Jeremy Cetnar
- Bellinda L. King‐Kallimanis (ORCID: https://orcid.org/0000-0001-9418-9374)
- Jill Feldman
- Emily L. Paton (ORCID: https://orcid.org/0000-0002-0603-1196)
Institutions
- Oregon Health & Science University (US)
- Walgreens Boots Alliance (United States) (US)
- Deerfield (United States) (US)
- LUNGevity Foundation (US)
Publication Details
- Journal
- JNCI Journal of the National Cancer Institute
- Published
- 2025-05-05
- DOI
- https://doi.org/10.1093/jnci/djaf108
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00